 10 AM / Updated 14 minutes ago BRIEF-Biohaven says U.S. FDA has notified co it may proceed with clinical investigation of BHV-5000 Reuters Staff 
Jan 18 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd: 
* BIOHAVEN ANNOUNCES INITIATION OF CLINICAL DEVELOPMENT FOR BHV-5000, A NOVEL LOW-TRAPPING NMDA ANTAGONIST 
* BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD- U.S. FOOD AND DRUG ADMINISTRATION HAS NOTIFIED CO IT MAY PROCEED WITH CLINICAL INVESTIGATION OF BHV-5000â€‹ Source text for Eikon: Further company coverage: